Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021096 | 0.84 | ADORA2A (0.45) | TLR8ADORA2AADORA1PDE5AKDM4E | |
| SCHEMBL5339452 | 0.80 | TLR8 (0.71) | TLR8KDM4EALDH1A1MAPTPKM | |
| SCHEMBL6265796 | 0.75 | TLR8 (0.51) | TLR8KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25432056 | 0.74 | ADORA2A (0.54) | ADORA2AADORA1KDM4EALDH1A1ADORA3 | |
| SCHEMBL6861398 | 0.73 | TLR8 (0.50) | TLR8ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL27659072 | 0.72 | RPS6KB1 (0.76) | TLR8KDM4EALDH1A1MAPTPRKACA | |
| SCHEMBL9662002 | 0.71 | CDK1 (0.34) | ADORA2AADORA1ALDH1A1ADORA3BRD4 | |
| SCHEMBL259023 | 0.71 | PDE10A (0.51) | TLR8KDM4EALDH1A1MAPTPKM | |
| SCHEMBL28427170 | 0.71 | TLR8 (0.82) | TLR8KDM4EALDH1A1MAPTPKM | |
| SCHEMBL925430 | 0.69 | NPSR1 (0.42) | TLR8KDM4EALDH1A1MAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | TLR8 2358/4885ADORA2A 352/4885ADORA1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.